Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition

A subset of lung adenocarcinomas is driven by the EML4‐ALK translocation. Even though ALK inhibitors in the clinic lead to excellent initial responses, acquired resistance to these inhibitors due to on‐target mutations or parallel pathway alterations is a major clinical challenge. Exploring these me...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EMBO Mol Med
Egile Nagusiak: Paliouras, Athanasios R, Buzzetti, Marta, Shi, Lei, Donaldson, Ian J, Magee, Peter, Sahoo, Sudhakar, Leong, Hui‐Sun, Fassan, Matteo, Carter, Matthew, Di Leva, Gianpiero, Krebs, Matthew G, Blackhall, Fiona, Lovly, Christine M, Garofalo, Michela
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7338803/
https://ncbi.nlm.nih.gov/pubmed/32558295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201911099
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak